Robert Konrad, Eli Lilly and Company, USA, discusses current understanding of the role of ANGPTL8 and presents data showing the effects of an anti-ANGPTL3/8 antibody in blocking ANGPTL3/8-mediated LPL inhibition in vitro and lowering triglyceride levels in vivo.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
